Navidea Biopharmaceuticals, Inc Blog | Talkmarkets | Page 1
No data available
No data available
Latest Posts
1 to 7 of 7 Posts
Week In Review: Xynomic Signs $502 Million Deal For Boehringer's RAF Inhibitor
Article By: ChinaBio® Today Saturday, November 4, 2017 4:58 PM EDT
Xynomic Pharma, a US-Shanghai clinical-stage oncology drug developer, acquired exclusive global rights to a 2nd-generation RAF inhibitor from Boehringer Ingelheim. Xynomic, hoping BI 882370 is a best-in-class drug, agreed to a $502 million package.
In this article: BLRX, ILMN, TEVA, NAVB Also: INTC, BABA
Read
Sapiens International & Navidea Biopharmaceutical - Sell Signals
Article By: Jim Van Meerten Saturday, November 7, 2015 2:25 PM EDT
Today I deleted Sapiens International (Nasdaq:SPNS) and Navidea Biopharmacuetical (NYSE:NAVB) for the Barchart Van Meerten Speculative portfolio for negative price momentum.
In this article: SPNS, NAVB
Read
Buy Signals - ABCD, CACB, NAVB
Article By: Jim Van Meerten Wednesday, July 15, 2015 2:14 PM EDT
Today I added Cambium Learning Group, Cascade Bancorp and Navidea Biopharmaceuticals to my portfolio for superior price performance.
In this article: ABCD, CACB, NAVB
Read
EC Our 3 Potential Triple Digit Biotech Winners Revisited
Article By: Bret Jensen Tuesday, February 10, 2015 2:29 PM EDT
We’ve enjoyed a lot of success with biotechs lately, most notably Avanir that got bought out and gave Small Cap Gems subscribers a profit of 214.7% in only five months.
In this article: NAVB, INCY, AGEN, CRIS, AVNR
Read
2 Triple Digit Winners For Under $2
Article By: Bret Jensen Wednesday, January 21, 2015 8:12 AM EDT
Small companies in the biotech, medical device, and biopharma spaces are inherently volatile and tend to have many bumps in the road as they try to establish their businesses in a very competitive market.
In this article: NAVB, ETRM, ZLTQ, LCI, AGEN, HALO
Read
Finding The Next Triple Digit Biotech Winner For 2015
Article By: Bret Jensen Friday, December 26, 2014 5:32 PM EDT
Biotech stocks can reward investors with gains other industries just can’t match.
In this article: AGEN, NAVB, CRIS
Read
Thinking Differently About Ebola Virus Disease: WBB Securities' Steve Brozak
Article By: The Life Sciences Report Friday, November 14, 2014 6:49 AM EDT
Mdtech analyst that has allowed the WBB Securities cofounder to develop a reasoned perspective on how West Africa's Ebola epidemic might be humanely halted. Brozak also mentions small-cap names that could considerably enhance investors' portfolios.
In this article: GSK, JNJ, NBS, BCRX, OMER, TKMR, CEMP, SRPT, CMRX, TTPH, NAVB
Read
1 to 7 of 7 Posts